Still winning.

The COMBI-AD trial was one of the landmark trials to show improved relapse-free survival with 12 months of dabrafenib and trametinib in patients with stage III, BRAF V600E/K-mutated melanoma. Long-term follow-up now shows a persistent benefit with dabrafenib/trametinib improving the rate of relapse free survival at 5 years from 36→ 52% and the rate of distant metastasis-free survival from 54→ 65%. | Dummer, N Engl J Med 2020